Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans

Diabetes

Volumn 47, Issue 4, 1998, Pages 640-645

  Kahn, Steven E ^a,f   Verchere, C Bruce ^a   Andrikopoulos, Sofianos ^a   Asberry, Pamela J ^a   Leonetti, Donna L ^d   Wahl, Patricia W ^e   Boyko, Edward J ^b   Schwartz, Robert S ^c   Newell Morris, Laura ^d   Fujimoto, Wilfred Y ^a  

^a Division of Metabolism   (United States)

^b General Internal Medicine Clinic   (United States)

^c Department of Medicine   (United States)

^d Department of Medicine ^*  (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; IMMUNOREACTIVE INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

AMYLOID; ASIAN AMERICANS; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; JAPAN; MALE; MIDDLE AGED;

EID: 0031895880     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.4.640     Document Type: Article

References (43)

1. Porte D Jr. β-cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
2. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of :Pima Indians. N Engl J Med 329:1988-1992, 1993
3. Chen K-W, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW, Fujimoto WY: Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM: 5-year follow-up of initially non-diabetic Japanese-American men. Diabetes Care 18:747-753, 1995
4. Maclean N, Ogilvie RF: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 4:367-376, 1955
5. Saito K, Yaginuma N, Takahashi T: Differential volumetry of A, B, and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med 129:273-283, 1979
6. Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417-421, 1978
7. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159, 1988
8. Howard CF Jr. Longitudinal studies on the development of diabetes in individual Macaco, nigra. Diabetologia 29:301-306, 1986
9. Johnson KH, O'Brien TD, Jordan K Westermark P: Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol 135:245-250, 1989
10. Opie E: The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 5:527-540, 1901
11. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci USA 84:3881-3885, 1987
12. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632, 1987
13. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634-638, 1990
14. Butler PC, Chou J, Carter WB, Wang Y-N, Bu B-H, Chang D, Chang J-K, Rizza RA: Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39:752-756, 1990
15. Cooper GJS: Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 15:163-201, 1994
16. Johnson KH, O'Brien TD, Westermark P: Newly identified pancreatic protein islet amyloid polypeptide: what is its relationship to diabetes? Diabetes 40:310-314, 1991
17. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37:188-194, 1994
18. Hartter E, Svoboda T, Ludvick B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52-54, 1991
19. Fujimoto WY, Leonetti DL, Kinyoun JL, Newell-Morris L, Shuman WP, Stolov WC, Wahl PW: Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes 36:721-729, 1987
20. Fujimoto WY, Leonetti DL, Bergstrom RW, Kinyoun JL, Stolov WC, Wahl PW: Glucose intolerance and diabetic complications among Japanese-American women. Diabetes Res Clin Pract 13:119-129, 1991
21. WHO Expert Committee on Diabetes Mellitus: Second Report. Geneva, World Health Organization, 1980 (Tech Rep Ser. no. 646)
22. Ward WK, Paquette TL, Frank BH, Porte D Jr A sensitive radioimmunoassay for human proinsulin with sequential use of antisera to C-peptide and insulin. Clin Chem 32:728-733, 1986
23. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, Koda JE: Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42:576-585, 1996
24. Rittenhouse J, Chait BT, Bierle JR, Janes SM, Park DR, Phelps JL, Fineman MS, Qin J, Koda JE: Heterogeneity of naturally occurring human amylin due to glycosylation (Abstract). Diabetes 45 (Suppl. 2):235A, 1996
25. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663-1672, 1993
26. Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P: Colocalization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240-244, 1989
27. Kahn SE, Fujimoto WY, D'Alessio DA, Ensinck JW, Porte D Jr Glucose stimulates and potentiates islet amyloid polypeptide secretion by the B-cell. Horm Metab Res 23:577-580, 1991
28. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491-502, 1984
29. Phillips DI, Clark PM, Hales CN, Osmond C: Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286-292, 1994
30. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY: Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes 39:104-111, 1990
31. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD: The visceral adiposity syndrome in Japanese-American men. Obes Res 2:364-371, 1994
32. Mitsukawa T, Takemura J, Asai J, Nakazato M, Kangawa K, Matsuo H, Matsukura S: Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 39:639-642, 1990
33. Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97-102, 1992
34. van Jaarsveld BC, Hackeng WH, Lips CJ, Erkelens DW: Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects. Diabet Med 10:327-330, 1993
35. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL: Human islet amyloid polypeptide expression in COS-1 cells: a model of intracellular amyloidogenesis. Am J Pathol 147:609-616, 1995
36. Clark A, Saatl MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289, 1990
37. Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, Westermark GT, Leckstrom A, Westermark P, Steiner DF: Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 323:40-44, 1993
38. Hoppener JWM, Verbeek JS, de Koning EJP, Oosterwijk C, van Hulst KL, Visser-Vernooy HJ, Hofhuis FMA, van Gaalen S, Berends MJH, Hackeng WHL, Jansz HS, Morris JF, Clark A, Capel PJA, Lips CJM: Chronic overproduction of islet amyloid polypeptide/amylin in transgeruc mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia and hyperinsulinaemia. Diabetologia 36:1258-1265, 1993
39. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, Ensinck JW: Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43:1457-1461, 1994
40. Westermark G, Benig-Arora M, Fox N, Carroll R, Chan S-J, Westermark P, Steiner DF: Amyloid formation in response to β cell stress in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med 1:542-553, 1995
41. Verchere CB, D'Alessio DA, Kahn SE: Consequences of human islet amyloid polypeptide expression in transgenic mice. In Lessons from Animal Diabetes VI: 75th Anniversary of the Insulin Discovery. Shafrir E, Ed. Boston, Birkhäuser, 1996, p. 131-148
42. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, Kahn SE: Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496, 1996
43. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE: Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 11:206-211, 1995